投稿第一篇SCI，7月份收到编辑部回信，请问修回后中的机会大不大啊 - 论文投稿 - 论文写作

版块导航: 正在加载中...

客户端APP下载

论文辅导

申博辅导

登录注册

应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！

24小时热门版块排行榜

返回列表

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

常八九无二三

新虫 (初入文坛)

应助: 0 (幼儿园)
金币: 226.9
帖子: 27
在线: 3.2小时
虫号: 6467006

已领完

投稿第一篇SCI，7月份收到编辑部回信，请问修回后中的机会大不大啊: 领取红包 (小木虫手机app专属红包)

扫一扫，下载小木虫客户端

意见如下

Reviewers' comments:
------------------------------------------------------
Reviewer E:

The manuscript by Wu et al. reviews the role of Gli-associated oncogenes, in
particular Gli-1, in cancer development, and as a potential target for
cancer therapy.  Gli-1 is an important oncogene and is found to be
overexpressed in a variety of cancers. The manuscript provides a good
overview of the current state of knowledge of the role of Gli-1 in mediating
signalling through the Hedgehog pathway, and how alterations in Gli-1 may
contribute to cancer development.  The manuscript also focuses on the
potential of inhibitors of Gli-1 and other components of the Hedgehog
pathway to be used in cancer therapy.  An extensive reference list is
provided, covering relevant articles in the field.

However, there are two major issues with the current manuscript which must
be corrected before it could be published.

1. The grammar requires extensive correction, as the errors detract
significantly from the meaning of the key points, and would make it
difficult for readers to fully understand the points being made in the
review.

2. In particular in the discussion of inhibitors of Gli-1 and other
components of the Hedgehog pathway, a clear distinction must be made between
effects demonstrated in cell culture, models, in xenograft experiments in
animal models, and effects in clinical trials.  This distinction is not
clear in the present manuscript, and this will lead to confusion on the part
of readers as to the current state of development of Gli-1 inhibitors for
cancer treatment. For example, resveratrol is described as a medicine
(Section 1.3), but this may be an overstatement. A more critical analysis
of the data with regard to potential Gli inhibitors is required in order for
the review to be of maximum benefit to cancer researchers.

Reviewer L:

The work titled “Glioma-associated oncogene especially Gli-1 function in
the carcinogenesis and cancer targeted therapy” is based on an interesting
area. The work can be considered for publication; however, it needs some
serious revisions before its acceptance. The manuscript must be revised as
per following comments-
1. The title looks difficult to understand, it may be revised something like
Role of glioma-associated Gli-1 oncogene in the carcinogenesis and cancer
targeted therapy.
2. Information provided in the manuscript is not adequate as I can see few
important researches like “Scientific Reports 6, Article number: 22184
(2016)”, BMC Cancer. 2009;9:298, etc. are not included.
3. Language editing is also required as few phrases are written
grammatically wrong for example, “in abstract section - Glioma-associated
oncogene (Gli) belongs…”; “in introduction - therapeutic target for
cancers…; resveratrol and cyclopamine”; “GLI-1 CLOSLY RELATED”;
“Moreover,…”; “exerts anticancer effects through”; “ITRA, an
inhibitor of Smo”, etc.
4. Delete phrase “In our review, we summarized the Gli function in the
carcinogenesis and cancer targeted therapy” from introduction section as
it is also written in the abstract.

------------------------------------------------------
Editorial comments:

This MS covers a good topic. However, there are major concerns over the
presentation and the language quality. The following should be carefully
addressed by the authors:

1. The rationale and the significance should be clearly stated in the
introduction section.
2. The abstract should be expanded to cover the major findings in the field.
3. The references should be updated.
4. A professional editing for language and style is needed. A certificate
for such an editing should be provided when resubmitting this MS.
5. The CCDT format should be followed.

-----------------------------------------------------

发自小木虫Android客户端

[ Last edited by 常八九无二三 on 2017-8-27 at 14:56 ]

回复此楼